A Case of Liver Metastasis of Gastrointestinal Stromal Tumor That Was Resected after Treatment with Imatinib Mesylate and Sunitinib |
Jung, Gum-O
(Department of Surgery, Wonkwang University Hospital, Wonkwang University College of Medicine)
Chae, Kwon-Mook (Department of Surgery, Wonkwang University Hospital, Wonkwang University College of Medicine) Park, Dong-Eun (Department of Surgery, Wonkwang University Hospital, Wonkwang University College of Medicine) Shim, Hyeok (Department of Hemato-Oncology, Wonkwang University Hospital, Wonkwang University College of Medicine) Park, Sang-Hyun (Department of Radiology, Wonkwang University Hospital, Wonkwang University College of Medicine) Yun, Ki-Jung (Department of Pathology, Wonkwang University Hospital, Wonkwang University College of Medicine) |
1 | Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625. DOI ScienceOn |
2 | Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. DOI ScienceOn |
3 | Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932. |
4 | Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478. |
5 | DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58. DOI ScienceOn |
6 | Rankin C, von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - a phase III sarcoma group study S0033. Proc Am Soc Clin Oncol 2004;Abstract 9005. |
7 | Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14: 526-532. DOI ScienceOn |
8 | Sym SJ, Ryu MH, Lee JL, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 2008;98:27-33. DOI ScienceOn |
9 | Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13:1596-1603. DOI ScienceOn |
10 | DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-352. DOI ScienceOn |
![]() |